Licensing out: Try not to get benched
von Colin McCall und Justyna Ostrowska
Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents
von mehreren Autoren
IP: Licensing and insolvency
von mehreren Autoren
UK increases scrutiny of tech and life sciences deals
Mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future.
von Paolo Palmigiano
6 von 6 Insights
US buys up entire stock of remdesivir
Time to intervene?
Arbitration for life sciences companies
von mehreren Autoren
Legal advice privilege: where are we now?
von Georgina Jones
Patents diary June 2020: UK Supreme Court holds Regeneron's transgenic mice patents invalid
von Dr Paul England